logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Wallachbeth Capital Announces Purchase And Sale Of Lixte Biotechnology Holdings, Inc. (Nasdaq: Lixt)

Apr 13, 2022•over 3 years ago

Acquiring Company

WallachBeth Capital

Acquired Company

LIXTE Biotechnology Holdings

SetauketLending And InvestmentsFinancial ServicesProfessional ServicesBiotechnologyHealth Care

Description

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE's common stock at a purchase price of $2.00 per share in a registered direct offering. The gross proceeds to LIXTE from this offering are expected to be approximately $5.8 million before deducting the placement agents' fees and other offering expenses.

Company Information

Company

WallachBeth Capital

About

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, creating value for both issuers and investors. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions. WallachBeth Capital is a leading provider of institutional execution services, offering clients a full spectrum of solutions to help them navigate increasingly complex markets. The firm's website is located at www.wallachbeth.com. Related Linkshttps://www.wallachbeth.com SOURCE WallachBeth Capital LLC

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed